Podcasts about public policy director

Bloomberg Daybreak: Asia Edition

Play Episode Listen Later Aug 20, 2024 82:23 Transcription Available

Rod and Greg Show Daily Rundown – Monday, August 19, 20244:05 pm: Was Kamala Harris intoxicated during a recent public appearance? Several police officers believe she was. Rod and Greg discuss the issue, as well as other issues pertaining to the presidential campaigns.:05 pm: Derek Monson, Public Policy Director for the Sutherland Institute, joins the program to discuss the growing rumblings that a special session of the Utah Legislature be called to place a constitutional amendment on the November ballot that would give lawmakers veto power over ballot initiatives.6:05 pm: Utah County residents are up in arms over a proposed almost 50% property tax increase, which comes on the heels of an already approved 12% tax increase from the Alpine School District.

drinking taxes rod kamala going up utah county utah legislature public policy director alpine school district sutherland institute greg show rodarquette

Japanese Stocks Bounce Back as US Futures Rise

Play Episode Listen Later Aug 6, 2024 21:02 Transcription Available

Featuring: Ahmed Riesgo, Chief Investment Officer at Insigneo Nick Schoenmaker, Client Portfolio Manager at Drummond Capital Monika Bičkauskaitė, Public Policy Director at Key Elements Group Apple: https://podcasts.apple.com/us/podcast/bloomberg-daybreak-asia/id1663863437Spotify: https://open.spotify.com/show/0Ccfge70zthAgVfm0NVw1bTuneIn: https://tunein.com/podcasts/Asian-Talk/Bloomberg-Daybreak-Asia-Edition-p247557/?lang=es-es See omnystudio.com/listener for privacy information.

japanese stocks futures bounce back chief investment officer public policy director

Rod Arquette Show: Why is the Country so Polarized? Plus, Questions About Utah's Caucus Convention System

Play Episode Listen Later Jul 3, 2024 92:53 Transcription Available

Rod Arquette Show Daily Rundown – Tuesday, July 2, 2024:38 pm: Brett Tolman former U.S. Attorney and Executive Director of Right on Crime joins the program to discuss the Supreme Court decision that says former presidents can't be prosecuted for official actions taken while in the White House.5:05 pm: John Goodman, President of the Goodman Institute, joins the show to discuss his piece for Townhall.com on why the country is so polarized.6:05 pm: Derek Monson, Public Policy Director at the Sutherland Institute joins Rod to discuss his piece in the Deseret News about how the results of the primary elections in Utah raise questions about the caucus convention system.6:20 pm: Charles Lipson, Professor of International Politics at the University of Chicago and a contributor to The Spectator joins Rod for a conversation about the hard choice Joe Biden faces if he stays in the presidential race.6:38 pm: Judge Glock, Senior Fellow and Director of Research for the Manhattan Institute joins Rod to discuss the Supreme Court's decision to uphold a Grants Pass, Oregon law that that essentially bans homeless people from sleeping in public areas.6:50 pm: Steve Cortes, Founder of the League of American Workers joins the program for a conversation about his piece for Real Clear Politics on how swing state voters place the blame for high food prices squarely on Joe Biden.

Family child care providers are concerned about proposed regulations

Drivetime with DeRusha

Play Episode Listen Later Jun 18, 2024 10:19

There are a new set of proposed regulations for in-home child care providers in Minnesota. Julie Seydel, the Public Policy Director for the Minnesota Association of Child Care Professionals - and a provider herself, joins Jason to explain the issues she has with them.

minnesota concerned childcare care providers public policy director proposed regulations family child care

Big Tech and The Future of American Democracy with Katie Harbath

1050 Bascom

Play Episode Listen Later Apr 22, 2024 49:33

In this episode of 1050 Bascom, we were delighted to welcome back Katie Harbath to the podcast. Katie graduated from the UW-Madison School of Journalism with a Political Science major as well in 2003. After graduating, Katie's impressive career trajectory took her to high level politics and to Facebook where she served as the Public Policy Director for ten years. Katie is now Chief Global Affairs Office at Duco Experts and the founder and CEO of her own DC-based company, Anchor Change. With major concerns about whether Americans trust the electoral process amidst a historical presidential campaign season and controversy over proposals aimed at regulating big tech, we were grateful that Katie was willing to spend a little time with us to talk about big tech, AI, and the future of democracy in the United States. We learned so much and hope you will too.

united states ceo ai americans dc journalism political science big tech american democracy bascom public policy director katie harbath uw madison school anchor change

The current status of Alzheimer's in Utah

Play Episode Listen Later Apr 20, 2024 10:11

Hosts: Leah Murray and Greg Skordas Alzheimer’s is a serious disease on the people who have it and on the loved ones who are living with it. Luckily, research is ongoing and maybe someday we will have a cure. Jeremy Cunningham, Public Policy Director for the Alzheimer’s Association, joins Greg and Leah to discuss the current status of Alzheimer’s and what’s being done about it.

utah alzheimer's disease current status public policy director jeremy cunningham greg skordas

KSL at Night: 4-19-2024

Play Episode Listen Later Apr 20, 2024 81:07

Hosts: Leah Murray and Greg Skordas The status of women leaders in Utah This year is the 10th anniversary of the Women’s Leadership Institute, making it a great time to take a look at how much progress has been made for women leaders in Utah. Pat Jones, CEO of the Women’s Leadership Institute, joins Greg and Leah to discuss how the institute got started, how much progress was made, and what’s next for the future of women in Utah. What’s up in higher education: commencement and FAFSA It’s a busy time in higher education. All the kids are twitchy, professors are over everything, and staff are waiting for faculty and students to leave for the summer. Jessica Oyler, Vice President of Student Access and Success at Weber State University, joins Leah and Greg in a discussion about all the latest news relating to higher education, from free speech at the University of Southern California to the broken FAFSA system. The NHL is officially here in Utah! Yesterday, the NHL logo appeared on the Delta Center, proving that professional hockey is officially here! Kyle Ireland, Digital Content Producer for KSL Sports, joins Greg and Leah to discuss the big news and what it means for Utah. The Supreme Court to weigh in on criminalizing homelessness Homelessness is a serious issue not just locally, but also nationwide. There’s actually a Supreme Court case about how localities can manage homelessness because it’s an 8th amendment violation to move people who are homeless along. Leah asks all of her legal questions to Greg, our expert. Jury selection complete for Trump’s hush money trial For the first time in U.S. history, a former president is on criminal trial. And because there are multiple trials happening… Today Greg and Leah take on former President Trump’s hush money trial, for which the jury selection is now complete. A look inside Nancy French’s new book: Ghosted One of the political figures Leah follows is David French, who is a conservative writer for the New York Times. As a result, she began following his wife Nancy French, who has a new book out titled Ghosted. Jennifer Graham, Ideas and Culture Editor for the Deseret News, joins Leah and Greg to talk about a piece she wrote about the book for the Deseret News. The current status of Alzheimer’s in Utah Alzheimer’s is a serious disease on the people who have it and on the loved ones who are living with it. Luckily, research is ongoing and maybe someday we will have a cure. Jeremy Cunningham, Public Policy Director for the Alzheimer’s Association, joins Greg and Leah to discuss the current status of Alzheimer’s and what’s being done about it. Leah and Caitlyn gush about Taylor Swift’s “The Tortured Poets Department” album Taylor Swift’s new album is out, and there’s no better person to talk about it with than Caitlyn Johnston, Producer of Dave and Dujanovic at KSL NewsRadio. She and Leah are 2 of the biggest Swifties we know from the KSL NewsRadio team, and then there’s Greg.

Jeremy Cunningham shares data from the National Alzheimer's Forum

Play Episode Listen Later Apr 18, 2024 11:00

Hosts: Rusty Cannon and Greg Skordas Alzheimer’s disease is the fastest growing disease in our country right now. Jeremy Cunningham, Public Policy Director of the Alzheimer’s Association, just got back from attending the National Alzheimer’s Forum in Washington D.C. He joins the show with the national statistics they discussed during the congressional meetings.

washington dc data alzheimer's disease hosts forum public policy director national alzheimer jeremy cunningham greg skordas

KSL at Night: 4-17-2024

JCO Precision Oncology Conversations

Play Episode Listen Later Apr 18, 2024 60:14

Hosts: Rusty Cannon and Greg Skordas Rusty unpacks the Utah Taxpayers Association’s 2024 Beehive Family Report The Utah Taxpayers Association released their new 2024 Beehive Family Report today. The report looks into the tax burdens of the typical Utah family. As he’s president of the organization, Rusty digs into the highlights of what’s inside the report. Will the Arizona Coyotes come to Utah? The Arizona Coyotes are inching closer to relocating to Salt Lake City, Utah. Why Utah? How will this transition work? What will be the new team name? Kyle Ireland, Digital Content Producer for KSL Sports, joins the show with all the latest. Chris Stewart explains why he’s endorsing Rep. John Curtis A few days ago, it was announced that former Congressman Chris Stewart is endorsing Rep. John Curtis for his bid in the U.S. Senate race. He joins the show to explain the reason for his support as well as discuss life after Congress. What if Utah bans international students from playing varsity sports? The Utah High School Activities Association is proposing a new rule that would ban international students from playing varsity sports. Amy Donaldson, Executive Producer of Podcasts for KSL, has been following this story since 2 years ago. She joins the show to explain the argument behind the rule change. Amy Donaldson gives the inside look on Season 2 of The Letter podcast If you’re a fan of The Letter podcast, you’re in for a treat because Season 2 is officially here! Amy Donaldson, Executive Producer of Podcasts for KSL and Host of The Letter podcast, joins the show to give an inside look on what’s in store for the unexpected second season of the podcast. Jeremy Cunningham shares data from the National Alzheimer’s Forum Alzheimer’s disease is the fastest growing disease in our country right now. Jeremy Cunningham, Public Policy Director of the Alzheimer’s Association, just got back from attending the National Alzheimer’s Forum in Washington D.C. He joins the show with the national statistics they discussed during the congressional meetings.

podcasts washington dc utah congress letter alzheimer's disease senate hosts forum salt lake city executive producer rusty arizona coyotes chris stewart ksl john curtis public policy director amy donaldson digital content producer elementtoproof national alzheimer jeremy cunningham greg skordas utah taxpayers association

Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy

Play Episode Listen Later Mar 20, 2024 41:52

JCO PO authors Lauren C. Leiman and Dr. Emma Alme share insights into their JCO PO article, “Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care”. Host Dr. Rafeh Naqash and guests discusses increasing access to liquid biopsy for cancer, reviewing the barriers and examining the proposed solutions. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor of Medicine at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are excited to be joined by Lauren Leiman, Executive Director of BloodPAC, and Dr. Emma Alme, Public Policy Director at Guardant Health. They are both authors of the JCO Precision Oncology article titled "Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care." Our guest disclosures will be linked in the transcript. For the sake of this conversation, we will refer to each other using our first names. So, Lauren and Emma, welcome to the podcast and thank you for joining us today. Lauren Leiman: Thank you for having us. Dr. Emma Alme: Thank you so much. Dr. Rafeh Naqash: So, this article is an opinion piece that addresses something that is emerging and current and tries to connect it to something that is futuristic also and hopefully, will address a lot of different needs relevant to patients with cancer. For starters, since our audience is pretty diverse, could you tell us what the BloodPAC is? Since the article is somewhat a combined piece from different stakeholders, could you explain what this BloodPAC Consortium is as an entity and what is its role for this BloodPAC? Lauren Leiman: Sure, this is Lauren Leiman. The BloodPAC was formed almost seven years ago as an initial commitment to the White House Cancer Moonshot back in 2016. I was the head of external partnerships and had this idea with a colleague of mine, Dr. Jerry Lee: Could you accelerate the development and approval of liquid biopsy assays for cancer patient benefit if you were able to create some standards and frameworks for the field broadly, and also if you could aggregate data to support those standards and frameworks? So, we brought together about 20 different organizations across pharmaceutical companies, diagnostic partners, foundations funding in the space, government agencies, all to think through can we create these frameworks, are we willing to submit data. We were extremely successful in that first round, and by the end of 2016, we were able to have our first data deposit into- we built a BloodPAC Data Commons, which is housed in Chicago and was created by Dr. Bob Grossman up there. In 2017, when it became clear that the last administration was not going to continue the White House Cancer Moonshot, we became an independent non-profit 501(c)(3). And we have grown substantially since that time from those original 20 different organizations to about 66 different organizations today, across all those areas again, including today, payers, which is very exciting. And we have added on to our mission statement one word that we will discuss today, which is very exciting, which is “accessibility”. After our five-year anniversary and even slightly before then, we decided that we really feel that we have been able to contribute, as a community, to accelerating the development and approval of these tests. But, in actuality if we don't get them into patients' hands, what is the point of all of our hard work? So, we added the word "accessibility." Today, we have these 66 different organizations that collaborate, essentially, to compete. They're pulling together projects and deliverables in about ten different working group areas to contribute products to the liquid biopsy community to help accelerate those three things. Dr. Rafeh Naqash: Thank you for explaining that. That seems like a very important initiative. Now, when you say that you're contributing data, does it mean that different companies and entities are contributing patient-level data so that you can pool that and assess what is the utilization, what is the utility, what is the payer-related aspects, coverage aspects. Is that all part of the initiative? Lauren Leiman: It is. We started with the idea, which is kind of scary, I think, for a lot of different companies: Are you willing to submit your protocols essentially, pre-analytical data? I think, much to the FDA's surprise, I was kind of, “Of course, everyone should be willing to do this, they should absolutely do this, it'll be really exciting. Why wouldn't they?” And I think others were a little skeptical that these companies who are highly competitive including Emma's company, Guardant, would be willing to contribute data. And in fact, Guardant is probably one of the first ones, first two at the table to actually submit their data which was just extremely exciting. And the data was around mostly protocols and pre-analytical variables, what tube types are you using? As we moved on, our pharmaceutical partners did submit full clinical trials with deidentified patient data, which was extremely exciting. Today, our Data Commons sits in two different areas or visibilities for our members. One is membership-only data that only our members can see, so have been been contributed by them potentially sometimes for certain projects we're working on. And then we also have an open segment of our Data Commons that's open to the public, that includes published data and studies that anyone can take a look at and see. Our goal is to continue to open up all of our data over time, so that anyone can take a look at it. We are, I think, the leading liquid biopsy repository. As we move into the future though, I think because we are mostly an organization that has pharmaceutical companies and diagnostic partners, we are company driven, aggregating large sums of research data is not necessarily their goal. And so to try to identify an area of mutually beneficial interests for everyone, I do think that over the next year or two, you'll see a potential shift or pivot in the use of Data Commons to where the industry is today which is probably, hopefully a little bit more coverage focused. How do we pivot from being a source of aggregated research to a source of identifying and approving the value of liquid biopsy to the full community? And again, that's for the full spectrum all the way through payers and the coverage of these tests, which I do think would add a tremendous amount of value to everyone on the life cycle of this industry but would also add a tremendous amount of value for access in getting these tests into patients' hands. Dr. Rafeh Naqash: Of course, you importantly covered a bunch of different concepts. One is data democratization, which is extremely important in the current day and age for different people in the public domain if they have access to data, they can do a lot of interesting and important things and add to the overall understanding of what we know or don't know in this space of liquid biopsy utilization. And then, of course, the aspect of disparities and coverage assessments. Now, going to Emma, for the sake of our listeners, some of them are trainees, and many of them are oncologists, perhaps many are patients. What is the current landscape for liquid biopsies? Where do we use them, and what are the general approaches and principles of where things stand? Dr. Emma Alme: That's a great question, and it really spans the cancer care continuum. And I think the space where it's most established is in the advanced cancer stage for therapy selection. So that's where we actually have some even FDA approved assays for liquid biopsy, with Guardant 360 test being one of them. It's comprehensive genomic profiling to identify actionable biomarkers to get patients on targeted therapy. So that's where it's really been integral to precision medicine. And we're seeing an increase in utilization of liquid biopsy as the technology becomes more established. It's not just in cases where tissue is insufficient now. Most recently, we've seen NCCN guidelines and non-small cell lung cancer change for concurrent testing for liquid biopsies. So that's been an exciting trend in adoption. And then as you move across the cancer care continuum, there's residual disease monitoring and response, where we can actually use ctDNA to look at a patient's response to therapy, even after surgery - is there still ctDNA there? Instead of just having imaging as an option, we can actually look sooner to see how the patient is responding and if there is still cancer present. So that's a really exciting place where we're seeing growth in liquid biopsy. And then moving even earlier, before a patient even has cancer, there's a tremendous opportunity for liquid biopsy in early cancer detection. I think that's something that has been previously discussed on this podcast and we see it a lot in popular media. But it's not just for multi-cancer, we have the opportunity for single cancer as well liquid biopsy tests in cancer screening. That's a really exciting space, really thinking about the accessibility of these tests. Because a lot of cancer screening modalities today are hard for a lot of patients to access. And it requires going to a medical facility. So if the first step is a blood test, that really opens that up to communities that traditionally have been left out of screening. So I think there's a huge opportunity there, not just when we're thinking about screening for cancers that don't have screening modalities currently, but also screening for those that do, where maybe a first non-invasive step can really open the door to patients who don't have access. So it's a long answer to say that, really, it's across the entire cancer care continuum. We see a lot of opportunity here for liquid biopsy to be a way to advance the field but also increase access for patients who have been left out of precision medicine. Dr. Rafeh Naqash: I think access is definitely the focus here. And I can give you my example. So I do early phase drug development and I do a lot of research in liquid biopsies and ctDNA monitoring. In the center of care, I treat people with lung cancer also and there have been instances, probably about a year or a year and a half back, where a patient could not come to the clinic. The clinic wasn't done and on my to-do list for that individual patient, I put in ctDNA testing just to remind me when I see the patient, to get it done. But the patient didn't make it to the clinic. Surprisingly enough, mobile phlebotomy was available. And later I came to know that this is something that can be done and provided to the patient at their home and you can still get the same results, which was very surprising in a good way. And it did help in making some treatment decisions for some patients who, sometimes in a state like Oklahoma, which is where I am based, we have a significant rural population and people drive six hours for some of our trials, especially the early phase trials. And then if you tell them, “Well, if you don't make this appointment, XYZ cannot get done,” it doesn't necessarily change things for them. So something of this sort definitely helps. Now, going to Lauren, I noticed this interesting sentence in the article, "fork in the road," where you describe, based on the current practices and policies, in the direction that we're going in, we can either increase or deepen the divide and disparities or decrease it. Could you tell us a little bit more about what currently exists on the disparity side and how do you see us narrowing that gap in the near future and implementing something that is equitable? Lauren Leiman: What's exciting about this paper is I think as we are talking about trying to condense this discussion down to something that's really digestible for everyone in the community, there are six barriers that we've identified. And I also should start by saying the working group that we have within BloodPAC that wrote this paper is intended to look at two different areas. One is that broadly, liquid biopsy still isn't available for the majority of the population domestically here in the US so that's a problem. In addition, it's clearly not available in underserved areas, and that's an even deeper divide. So we're kind of at this fork in the road because it's not broadly accessible to the majority of patients today. And so we have this moment in time where we're able to make a decision to bring everyone along with us, which is very exciting but also will take a lot of work. And these six barriers that the paper identifies, I think are very clearly articulated. They are: lack of uncertainty around test performance, the lack of familiarity with this technology, inconsistent payer coverage is an issue, mistrust of the medical establishment - especially in underserved areas, fear of discrimination in seeking this kind of technology, and the difficulty with terminology. I think that the whole liquid biopsy community has a role to play in addressing these six areas. I think that BloodPAC, in particular, as a consortium and a collaborative process for 66 different organizations that work in the field, we have a role to play, most certainly in helping to address specifically some of these areas. We have working groups that specifically address reimbursement and policy, so that would obviously fall into payer coverage of these tests. We have working groups creating lexicons both in the molecular residual disease area, as well as our multi-cancer early detection areas. So creating terminology and lexicons that are consistent across the entire community and also digestible for patients, which is really important. And so mitigating these barriers is going to be a collaborative process across all stakeholders in the liquid biopsy field. And I think BloodPAC is uniquely positioned to address many of these because of our diverse stakeholders and membership, which is exciting. But I do think that this is the perfect moment in time now to start addressing these challenges, and we shouldn't wait much longer, as we think through how we can bring everyone along with us and make sure we're not leaving anyone behind. Dr. Rafeh Naqash: As this entity or consortium, as you call it BloodPAC, has moved forward, this is a question for both of you, Emma and Lauren. Emma, I guess you can start. How were things five years back? What are some of the things that you have been able to achieve, and where do you potentially see the next five years? Dr. Emma Alme: I think we have made a lot of strides on the coverage side when it comes to advanced cancer testing for liquid biopsy. By no means are we there by any stretch of imagination, but we're starting to see some coverage adoption, which does make a huge difference because at the end of the day, that's so important to ensure equitable access. Especially when we're talking about a technology that has the potential to close some of the barriers in precision medicine because of the fact that you don't need access to some of the medical facilities, as you pointed out earlier, rural patients don't have access to. Because transportation is not necessarily a barrier here the way it is for some for some of these other treatment aspects. But if you don't have consistent pay or coverage, that's a place where you're really going to see drop off in terms of patients not getting equitable care and not getting standard of care as liquid biopsy enters into that realm. The increase we've seen in private payers adopting coverage, the way we see Medicare coverage for advanced cancer liquid biopsy, is encouraging. We've seen states adopt legislation to require coverage of biomarker testing, that's passed in 15 states now, thanks to the work of the American Cancer Society and a broad coalition of stakeholders. I think that's beginning to make a difference, but we have a long road to go. We still, on the MRD side, that's just emerging. And so one space where we have some recommendations on this is continued evidence generation - continue to gather that clinical utility data that will support payer adoption increasing on the advanced cancer side, but then moving across that cancer care continuum to those other types of liquid biopsy tests. I think that's hugely important and there's a role for BloodPAC to play in that as well, especially in making sure that we bring everyone to the table to have these conversations on what is the evidence that, we need to generate, what should that look like, what are the standards to ensure that everyone feels confident in these tests. That's one area that we're really excited to see. And I also think another space is on the diversity in clinical trials. It's so important to make sure that when we are bringing these tests to market, the data that we gather to support that is representative of all patients who can benefit. It is so important to make sure that the tests work, but also to build confidence in all of the people who are going to get these tests and feel like, “Okay. I know that this test works for patients that look like me, too.” And so that is something that at Guardant we are working really hard on. We read out our clinical trial, ECLIPSE, for our blood based test screening for colorectal cancer a little over a year ago, and we were really happy to be able to say that our trial was representative of the US population, particularly for Black Americans, where colorectal cancer incidence is increasing, 30% to 40% higher rates of mortality, in Black patients than White patients for CRC. So it's especially important to make sure that the population is representative in the clinical trial of the patients who will benefit. And I think we are seeing companies increasingly realize their responsibility in that space and it's something that we can all really prioritize moving forward with things like making sure transportation is accessible to patients, making sure that clinical trial materials are accessible, culturally sensitive in a broad set of languages. There are a lot of different activities. You have mentioned mobile phlebotomy earlier, that can be incorporated into trials working with community centers and not just academic medical centers to ensure that the trials are taking place close to where patients live and work. This is a tractable problem and I think we've made a lot of headway in the five years. But looking to the future, there's still a lot more we can do together to ensure that work continues. Dr. Rafeh Naqash: All excellent points. And I completely agree with you. Bringing the trial to the patient is more important and likely to lead to better outcomes than the patient driving six hours to a facility to come on for trial. So, the question for Lauren that I have from a physician or scientist standpoint, is what gets covered or does not get covered is not necessarily that I know about in my daily clinic of 15-20 patients. What is the difference between different states having different coverage policies for something like this? If it's the same payer in state A and the same payer in state B, why is the coverage policy in state B different from that in state A? And what are some of the things we can do locally and at a national level to help bridge some of these disparities and gaps? Lauren Leiman: I'm going to hand that question over to Emma. This is her bread and butter. Dr. Emma Alme: That is such a great question, and I wish I had a more satisfactory answer for you. The reality is that when it comes to diagnostics, coverage is really a patchwork, compared to when we think about drugs whether it's FDA approved, we expect to be covered. With diagnostics, it's really up to the insurer. And I keep going back to the advanced cancer space because that's where we see the broadest coverage because it has been around the longest. But we see broad coverage from Medicare for these types of tests. But, for private payers, it's really a patchwork. We see a lot of payers only just starting to cover these tests, maybe where there's a CDX indication with an FDA-approved drug we see it, but not more broadly for tumor profiling. Especially not for the larger, more expensive comprehensive genomic profiling panels that are more expensive. I think you can extrapolate the obvious reasons why that might be. But, as this is being moving into NCCN guidelines, we see very slow adoption by some private payers. And you touched on the legislation in different states. This coalition on American Cancer Society has been spearheading is trying to pass state-level legislation that will align coverage with a strong, robust set of evidence, and that's an FDA-approved companion diagnostic indication, medicare coverage, whether it's an NCD National Coverage Determination, a Local Coverage Determination, or National Clinical Practice Guidelines like NCCN, so really a robust set of evidence. And so this is resonating with state legislators across the country where we are seeing that take off in 15 states. But the political climate is different in different states so there are differences in terms of which state will adopt this, some of the differences are in language that they put into this. But even now that these are passing, we're seeing differential implementation, some plans are not necessarily reading this legislation and saying, “Okay, I have to cover all the tests that Medicare covers.” They are thinking that maybe they have some agency to put on other medical necessity criteria. So I think there's a lot that will play out on the individual state level to see how this nets out. But it's really kind of how different insurance companies and plans are interpreting these mandates, are interpreting guidelines, etc. But you touched on the differences between the states and one of the things that has actually been shown in data from the precision medicine coalition is that even when you change insurance coverage for one individual plan, it doesn't necessarily translate into adoption in the direct correlation that you would expect. And part of that is because it's such a patchwork and it's so chaotic. Providers don't necessarily know for their patients which plan will cover, which one won't. They're very hesitant to subject their patients to out of pocket costs and so you get providers being reticent to order liquid biopsy just because of this coverage landscape. And so there really is that need not just to go step by step but get broader coverage for these patients across the board. And so I think the long term vision is can we get to a change at the federal level. That's hard compared to the state level. It's a long road ahead. That's why I started this with I don't have a satisfactory answer. There is still a lot of chaos ahead even though we made some progress along the way. Dr. Rafeh Naqash: I completely agree. Lots of things to do together. But, in my daily role as a physician or a scientist, I come across situations where a patient's situation was denied for liquid biopsy, then the company went and appealed or insurance doesn't want to pay for it, and then they ask for peer-to-peer review, which is a lot of time and energy on the provider's side, the physician's side, even for as simple as a CAT scan for cancer, let alone a liquid biopsy. I started thinking at that time, is there a scenario where if I were ordering a Guardant or a foundation or any liquid biopsy for that matter, can they not provide additional support where I don't have to do a peer to peer and I can spend time and energy concentrating on the more important patient issues that are right in front of me, rather than having to wait for an insurance company to call me at a certain time of the day where I may or may not be available and then having to reschedule the call and spend another 30 minutes to them explaining. So I don't know if you guys on the other side of the aisle also think about some of these issues, but could that be a scenario that could potentially be implemented in the near future? Dr. Emma Alme: Yes, absolutely. This is something that we at Guardant think about a lot. One of the challenges is that, as a laboratory offering liquid biopsy, you are an ancillary provider, and so I think you touched on it, a lot of this role falls to you as the physician to secure prior authorization and to be the patient's advocate. And not all plans – this is often true for Medicare Advantage – allow the laboratory to be the one to, for example, initiate prior authorization and provide the medical necessity information to make sure that that test is approved by the insurance company, and then to be the advocate for that patient in appeal process as you mentioned. And I think there is a lot of education that needs to happen among policymakers to make some tweaks to this process to ensure that the patient can have access, that the laboratory can be involved in the process where it makes sense, to smooth out this process. And exactly right, I think you touched on a place where it is a huge burden for providers. There are places where the laboratory is best equipped to move the patient through that process and there's a lot of red tape that we can help overcome. And that's not specific to liquid biopsy. I think that's true across the diagnostics industry. But you're exactly right that it is another hurdle to access is if this is a process that has a lot of red tape. So I'm pleased to hear you think about this the same way. Dr. Rafeh Naqash: I'm glad you guys are having those conversations, having conversations is the first important step to make a change in the near future. If there's a patient listening out there and that patient has gotten a recent bill of $5,000 for liquid biopsy, what are some of the steps that you would like to highlight for them from a patient standpoint so that they can advocate for themselves? And should they talk to the physician in the company? Should they directly approach the company to not have that additional financial toxicity in situations where it may not be covered? Lauren Leiman: I would 100% encourage those patients to please reach out to the company. I can only speak for Guardant but we have a patient access program. Our team calls any patient that's going to have more than $100 out of pocket because our goal at Guardant is to make sure that patients have access to the testing they need to inform their treatment and get the best possible care. I think we're all aligned across these companies across both- like we want to make sure that we are lowering the burden for cancer patients. There's already so much stress on these patients initiating treatment. They don't need to have the added stress of battling insurance. So we're here to help and no patient should be on their own in that space. So please tell your patients to reach out to the company in those instances, but I would hope that they would already have gotten outreach from the company in the first place. Dr. Rafeh Naqash: I often discuss with some of my colleagues about the financial burden of cancer care, unfortunately, that people tend to have. And I remember this scenario a couple of months back where a patient of mine, when I sat down in the clinic room, they had this big, thick folder with them. And after I finished the discussion about what was going on with the cancer, they said, "Could you help figure this out?" And they opened this folder. It had so many bills, and one of the bills was obviously a liquid biopsy bill. And that was my understanding, too, that there is a lot of resources available to these people. And eventually things worked out. The company took the cost of whatever was not being covered by the insurance. But again, you touched upon an aspect in the article about educating the physicians, the providers. I think definitely a lot of work needs to be done there so that the patients can advocate for themselves and the healthcare providers can advocate for the patients, too, like having those checks and balances and those resources present and in the institutions where these people get cared for or knowing what's the right way to channelize these issues and to whom within the companies, so that all of this gets taken care within a timely period, so that the patient doesn't come back with the same issue six months later, “I still have this bill,” that even if it's being sent to the patient or their family by mistake, it does add a lot of psychological pressure. So I think a lot of things potentially need to be done in that space, and hopefully you guys are still doing that and continue to do that, make progress in that space to help mitigate and alleviate some of that patient level burden, which is extremely crucial in their care. Lauren Leiman: I think what's interesting about what we're looking at now is BloodPAC is thinking through these financial challenges, the coverage challenges for someone who's probably made it to an academic center to access these tests to begin with. And so to go back a little bit in the conversation, I think there still are challenges, which I'd love to hear more about from the experience of a clinician. But we have talked about, does mobile phlebotomy access everyone? Is it capable of providing access for everyone? I don't know. There's new technologies that we are looking at, like home blood collection. Most of the companies that we work with right now, they're not getting enough quantity. The quantity isn't there. But is that something that we should be pursuing? Because as you've already said, people drive six hours, and sometimes you can't make that drive. And sometimes a mobile phlebotomy lab is not able to get those six hours away. There's a limit on how far they can go. That's a huge challenge. I'm also fascinated by the idea that if you were to eliminate coverage as an issue, so if we were to say we're offering tests for free, is there still the educational barrier, the understanding barrier that we are not putting enough emphasis on? I don't know the answer to that question. I think there is a large element to that, though. And I think that when you say education, I have asked colleagues, "Okay, guys, who are we educating? Are we educating the clinician on specific tests? Are we educating the community health worker somewhere else outside of an academic center? Are we educating the patients themselves? Do they need to really understand exactly what this kind of futuristic technology is and what it can do for them?" Those are a lot of permutations of what if, what if, what if, what is the barrier? And so to take a step back, the reality is for that big bucket of individuals that I talked about at first, yes, coverage is going to be the primary barrier for them. But if you were to remove that barrier for some individuals, I think you still have a lot of challenges left ahead of you, which is essentially what the paper is saying. But I think that that is the really big question that I still have in my mind. If we can eliminate coverage, what's left and how do we address it? Dr. Rafeh Naqash: To that point, I would like to add also- you pointed out educational barriers and there's definitely educational barriers on the provider side also, physicians, whether it's academic or community, that's a different discussion altogether. And this is not just one example, but this is an example that I'm giving because there's several other examples similar I've seen where somebody gets a liquid biopsy done in the community setting, or maybe even in an academic setting somewhere else. And somebody like me who deals with some of these results, I do a lot of precision medicine, I do a lot of genomics, but that's not everybody's interest or forte. That's not something that everybody's necessarily interested in or I try to read each and every detail in a report and understand implications, and not everybody necessarily thinks that that's the best utilization of their time. And I have identified a lot of patients that have been in the system within our state or outside our state where liquid biopsy two years back showed a certain potential germline mutation with a very high variant allele frequency and never got any germline testing. And then I see the patient and I start connecting the dots and the patient gets germline testing done - patients is positive, children are positive, children get XYZ procedures done as part of surveillance or mitigation strategies to prevent future cancers, which again, prevention is cure. At the end of the day, you catch something earlier, as we all know, higher chances for cure. So I think that part of education, we still need to do a lot more on educating the providers, the physicians, or making it somewhat easy, like is there a way that, well, if you have a potential finding of a germline mutation, let's say on a report, instead of just mentioning the potential of germline mutations, maybe we can go to the next level and offer free germline testing and free genetic counseling and make sure that you communicate with that provider versus the responsibility being on the provider or the physician that, “Hey, did you read this carefully? Did you miss something? Did you not miss something?” This is something I have come across and we're actually doing a project right now looking at some of that and analyzing the data and the percentage is pretty significant, and hopefully, if and when the results of that project are published, you will understand how much of a difference it actually can make in the lives of patients and their families to catch something early. Dr. Emma Alme: I think you raise a really good point and your example of germline testing along with tumor profiling is a good example of the kinds of questions that we'll encounter as liquid biopsy moves across that cancer care continuum. So I think we do have to be thinking about what kind of education will we be giving to providers for how they integrate, for example, MRD liquid biopsy testing with standard of care imaging, what does that patient management process look like? On the early cancer screening side, what happens when you get a positive test for a patient? What does that diagnostic workup look like? Especially when there isn't necessarily a standard of care screening pathway- isn't a diagnostic pathway. Whose responsibility is that? There are so many outstanding questions through how we think about provider education across this board that really will take all stakeholders together to really formulate what this looks like. I think you raise a really good point. Right now, I think we all have more questions than answers, but I think it's an important place for us all to be working really hard on right now, to ensure that this doesn't roll out in a way where there is confusion, especially where the providers offering liquid biopsy, maybe primary care physicians who aren't necessarily, as you said, going to be well versed in the literature on liquid biopsy, thinking about these tests report the way that you are right now. There's a lot of work to be done there. Dr. Rafeh Naqash: Absolutely. It was a pleasure talking to both of you about the science, logistics, and payer aspects. A couple of quick minutes on both of you as individuals. I like to start with you, Lauren, can you tell me briefly, what's your background? How did that background connect to what you're doing today? And what else have you learned in this process? Lauren Leiman: Sure. I am Lauren Leiman. I'm the Executive Director of BlooPAC. My backgrounds are primarily in communications and business and developing collaborations that are mutually beneficial for all participants. I have worked in finance. I've worked in Africa for many years for an economist and really decided during that time that health care and health initiatives were really what interests me and ended up working in a melanoma foundation for many, many years, developing interesting collaborations between academic institutions and funding formats, and took that to the White House for the first White House Cancer Moonshot as the Head of External Partnerships, and work towards identifying collaborations between different government agencies and different companies, as well as straight corporate commitments to the Cancer Moonshot, which was “a decade of progress in half the time”, the mission statement. And having worked in melanoma for a while and working at the Moonshot, I'd heard about this liquid biopsy technology. It's out there and I thought it was pretty cool. I have melanoma in my family, and was like, wouldn't it be really interesting if you could get your blood drawn and just tell me if I have melanoma as opposed to kind of scanning my body every six months? And my colleague Jerry Lee, at the time kind of dropped a ream of paper on my desk and said, “Read this.” So I'm neither MD nor PhD, I'm a lowly MBA, who went home and read through everything and came back and said, “You don't have a science problem. You have the collaboration problem, you need to work together, you need to share your data and share your information, which was kind of the birthplace I guess for BloodPAC - could we again, aggregate our data, bringing together these experts in the field to help accelerate the development and approval and accessibility of these technologies. That is my background. Again, an interest in things, going back to Africa and the time I spent there, I'm heavily interested in underserved populations, not just domestically but globally. My hope is that eventually BloodPAC starts really engaging in how do we increase access for all to these really exciting new tests? I do receive, BloodPAC and I as the executive director, receive calls probably once a month from different startups around the world saying, “Good luck with all your $500 test. I want a $5 test, how are we going to get there?” Which you know, I think is the absolute goal for everyone. But slowly but surely, I think we are going to work towards increasing access for all not just domestically here and not just underserved populations here in the US, but hopefully locally as well. Dr. Rafeh Naqash: Thank you, Lauren. Same question to you, Emma. Could you tell us about your background and how it led to your current work and some of the things you learned? Dr. Emma Alme: Absolutely, my background began on the science side. I did a PhD in biochemistry at UCSF University of California, San Francisco. About halfway through my PhD, which I think is a realization many have, I discovered that I loved talking about science and thinking about science and reading about science, but it would be okay if I didn't have to pick up a pipette again. At the time, I was so invigorated by all of the research going on around me but realized that, similar to what Lauren said, it wasn't the science that was the barrier in a lot of cases of this research really reaching patients and changing their care. There were so many policy barriers that were standing in the way of that that I felt like I really wanted to help tackle and so I was fortunate in the fact that there are a lot of fellowships out there for PhDs in science to move into policy roles and serve as science advisors, so I did a smattering of those all around DC. I worked at the National Academy of Science. I worked at NIH and then I went to Congress, where I was a Health Policy Fellow for Anna Eshoo and got to interact with so many different companies in the biotech space and learn about all of their amazing technology, including liquid biopsy that folks were working on where there again, were so many barriers to adoption, where there were policy solutions, and I got really excited to work on that. It was the perfect nexus of my background and biochemistry and genetics and health policy. And so the opportunity came up to work on policy for Guardant who was really thinking about those issues. And so I jumped at the chance to spend all of my time thinking about how do we increase access for patients? How do we make sure that this innovation actually gets into their hands through changes in coverage and reimbursement? And also thinking about most of the things that we've been talking about today - diversity in clinical trials, how we brought in education for patients and providers. So it's been a really exciting space to work in. It's been super fun to get to help the Guardant work with BloodPAC and I think it's an amazing group of collaborators that brings me a little bit back to my academic roots in terms of enjoying the kind of conversations that all these folks have together as we think about standards. That's been a really exciting place for me to sit in the health policy world combining all of that experience together. Dr. Rafeh Naqash: Thank you so much. It looks like all of you within the BloodPAC and perhaps outside the BloodPAC are people driven by a common vision and mission and hopefully will succeed in all of those things that you're trying to achieve. Thank you for giving us the opportunity to talk to you guys and thank you for publishing in JCO Precision Oncology. Hopefully we'll see more of your work with regards to implementation and some of the next steps that you're taking and perhaps even the data for some of these studies that you're combining together, within JCO Precision Oncology in the near future. Dr. Emma Alme: Thank you so much for having us. Lauren Leiman: Thank you. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe, so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Leiman COIs: Stock and Other Ownership Interests:Company: Illumina Company: Eli lillyAlme COIs:Employment: Company: Guardant Health Stock and Other Ownership Interests: Company: Guardant Health

Tango Alpha Lima Be The One EP07: Healing Breakthrough with Juliana Mercer

Tango Alpha Lima Podcast

Play Episode Listen Later Mar 1, 2024 36:30

Marine Corps veteran Juliana Mercer, Veteran Advocacy and Public Policy Director of Healing Breakthrough, discusses her work in advocating for the adoption of MDMA-Assisted Therapy in the U.S. Department of Veteran Affairs. Juliana talks about removing the stigma of psychedelics use, the experience of MDMA-assisted therapy, and the work her organization is doing to fulfill their mission of making this treatment available to veterans in the United States. Special Guest: Juliana Mercer.

Rod Arquette Show with Greg Hughes: Yay or Nay on Ranked Choice Voting

Relentlessly Resilient Podcast

Play Episode Listen Later Feb 15, 2024 96:47 Transcription Available

Rod Arquette Show with Greg Hughes Rundown – “Wingman Wednesday,” February 14, 20245:05 pm: Derek Monson, Public Policy Director at the Sutherland Institute joins Rod and Greg to discuss a new poll that shows Utah voters may favor Ranked Choice Voting despite a bill being considered by Utah lawmakers that would repeal a pilot project for the election system.6:38 pm: Senator John Johnson joins Rod and Greg for a conversation about his proposed General Education Act (SB226) that would require all students at state-funded universities to take required courses on Western civilization, American history and civics.

american western utah rod yay or nay ranked choice voting john johnson public policy director greg hughes sutherland institute knrs rodarquette rodarquetteshow talkradio1059

Alzheimer's planning, policy, and protections to know with Utah Alzheimer's Association's Jeremy Cunningham

Play Episode Listen Later Jan 25, 2024 51:58

As we continue our conversation on Alzheimer's disease and dementia, Jeremy Cunningham, Public Policy Director of the Alzheimer's Association Utah Chapter, discusses what families and caretakers of patients need to know. Issues from the causes and contributions to cognitive decline and medications, to the legal/scam protections and policy, as well as Adult Protective Services. Even if you do not have a loved one with Alzheimer's, it is important to learn about this ‘Silver Tsunami’ issue of public health. Even though we live in challenging times, we can become Relentlessly Resilient as we lean on and learn from one another’s experiences. Hosts Jennie Taylor and Michelle Scharf are no strangers to overcoming adversity; Michelle lost her husband to cancer, while Jennie’s husband, Major Brent Taylor, was killed in the service of our country. Their stories bond them together, and now listeners can join them weekly as they visit with others enduring challenges and who teach us how they are exercising resiliency, finding value in their grief, and purpose in moving forward. Presented by Minky Couture, makers of the most luxurious and soft blankets with a mission to share comfort and love during the special moments of life. Listen to the Relentlessly Resilient Podcast regularly on your favorite platform, at kslpodcasts.com, kslnewsradio.com, or on the KSL NewsRadio App. Join the Resilience conversation on Facebook at @RelentlesslyResilient and Instagram @RelentlesslyResilientPodcast. Produced by KellieAnn Halvorsen.

planning resilience utah policy alzheimer's disease hosts protections silver tsunami public policy director adult protective services jennie taylor jeremy cunningham major brent taylor ksl newsradio app

Dr. Tony Beam - Politics South Carolina-Style

Priority Talk

Play Episode Listen Later Jan 20, 2024 24:55

Dr. Tony Beam joins Greg to talk about the upcoming South Carolina Presidential Primary and some other legislative issues facing Alabama and South Carolina. Dr. Beam serves as Director of Church and Community Engagement at North Greenville University and is the Public Policy Director for the South Carolina Southern Baptist Convention, and the longtime host of Christian Worldview Radio.

director church politics alabama style south carolina community engagement beam north greenville university public policy director

Holiday gift guide for people living with dementia and their caregivers

Dave and Dujanovic

Play Episode Listen Later Dec 18, 2023 10:35

Nearly 7 million Americans struggle with Alzheimer’s. Depending on the stage of the disease, some gifts might not be the right ones for them. Jeremy Cunningham, Public Policy Director of the Alzheimer’s Association, joins the show to give some suggestions on holiday gifts you can give to loved ones with Alzheimer's, as well as their caregivers.

americans alzheimer's disease depending dementia caregivers holiday gift guide people living public policy director jeremy cunningham

Social equity & finance challenges in the cannabis industry

Midday

Play Episode Listen Later Oct 26, 2023 38:20

Cannabis is big business, and more than $420 million dollars of medical and recreational use cannabis was sold in Maryland in the first eight months of the year. When the General Assembly made recreational cannabis legal, it established a new Office of Social Equity, to assure that members of traditionally marginalized communities have access to the resources they need to establish businesses in this lucrative industry. Joining Tom to discuss social equity in the cannabis business is Audrey Johnson, the executive director of Maryland's Office of Social Equity. Next, Tom turns to Wendy Bronfein, the Co-Founder and Public Policy Director at Curio Wellness to discuss legislative initiatives to address finance and tax problems for the cannabis industry.Email us at midday@wypr.org, tweet us: @MiddayWYPR, or call us at 410-662-8780.

challenges co founders office finance maryland cannabis general assembly cannabis industry social equity public policy director curio wellness

Drug Supply Shortages

Healthcare Policy Pop

Play Episode Listen Later Sep 21, 2023 3:30

Gavin Clingham, Public Policy Director for the Alliance for Patient Access, discusses reasons behind drug supply shortages and some possible solutions; Patients Rising Now submitted questions to the E&C Oversight and Investigations Subcommittee pertaining to the IRA's drug price setting; and CMS will host listening sessions for the first 10 drugs named for price setting, but Patients Rising Now says more needs to be done. Alliance for Patient Access E&C Oversight and Investigations Subcommittee Hearing: "At What Cost: Oversight of How the IRA's Price Setting Scheme Means Fewer Cures for Patients" CMS Webpage: Medicare Drug Price Negotiation Program Patient-Focused Listening Sessions

alliance drug supply cms shortages patient access public policy director

Saying Yes to Opportunities with Kim McClellan: L2L

We Are Business

Play Episode Listen Later Jul 13, 2023 27:50

Leader 2 Leader Series:Join Chamber President and CEO, Susan Spears on a journey as she interviews some of the top community leaders in this series. Susan and her guests will share their insight and wisdom on making teams more effective, leveling up your communication skills, and building the courage to lead during difficult times. The Leader2Leader series is about making the most of it all —with insights, research, advice, practical tips, and expertise to help you become the leader you desire to be.Today's Guest: Kim McClellan, Public Policy Director, Fredericksburg Area Association of Realtors

ceo opportunities leader realtors saying yes mcclellan public policy director

Public Policy Director for the Utah Chapter of the Alzheimer's Association Jeremy Cunningham on FDA approval of new drug Leqembi

Jeff Caplan's Afternoon News

Play Episode Listen Later Jul 7, 2023 5:10

The FDA giving full approval to Leqembi...an experimental Alzheimer's drug. Public Policy Director for the Utah Chapter of the Alzheimer's Association Jeremy Cunningham joins Jeff to explain how the medication helps Utahns.See omnystudio.com/listener for privacy information.

utah alzheimer's disease fda new drugs fda approval ksl utahns public policy director leqembi ksl newsradio utah chapter jeremy cunningham jeff caplan

Why are New Treatments for Alzheimer's Disease Being Blocked?

Inside Sources with Boyd Matheson

Play Episode Listen Later May 18, 2023 9:41

Alzheimer's is a terrible disease that affects seniors in our country. Through pioneering science and research, treatments are being developed to combat the disease, and we're learning more about it all the time. However, access to treatment, especially new treatments of Alzheimer's, has been continually blocked by contradictory decisions made by different health organizations. How close are we to gaining access to critical treatments for this disease? Jeremy Cunningham is the Public Policy Director for the Utah chapter of the Alzheimer's Association, and joins the show to talk about the situation, and how to provide better care for Alzheimer's patients.See omnystudio.com/listener for privacy information.

Public Defenders and Political Advocacy: What Is a Public Defender's Role?

Teleforum

Play Episode Listen Later Apr 5, 2023 60:10

Over the past several years, a debate has erupted within the world of indigent defense: to what degree is it appropriate or indeed vital for public defenders to be involved in political advocacy? Some contend such advocacy is outside the role and responsibility of public defenders, who should instead focus on defending their clients to the best of their ability. Others assert that involvement on social issues that arguably affect their clients is integral to the public defender's mission and work.In this Teleforum former public defenders discussed these questions on the role of public defenders in political advocacy. Feauring:--Maud Maron, Interim Executive Director, Foundation Against Intolerance and Racism--Tiffany Roberts, Public Policy Director, Southern Center for Human Rights--[Moderator] Matthew Cavedon, Robert Pool Fellow in Law and Religion & Senior Lecturer in Law, Emory University School of Law

politics law religion political advocacy senior lecturer public defenders emory university school interim executive director public policy director southern center foundation against intolerance teleforum criminal law & procedure

Rod Arquette Show: New Utah Laws to Protect Our Kids at School

amazon head killing comparison mops nona jones public policy director mops international chief external affairs officer

Play Episode Listen Later Apr 3, 2023 103:45

Rod Arquette Show Daily Rundown – Friday, March 31, 20234:20 pm: Representative Ryan Wilcox joins the show for a conversation about how his recently passed school safety legislation will help protect Utah's children4:38 pm: John Zadrozny, Deputy Director of Investigations for America First Legal joins the program for a conversation about the indictment of Donald Trump5:05 pm: Donald Trump has been indicted, so what next? Former U.S. Attorney for Utah John Huber joins the show to discuss the next steps in the process6:05 pm: Townhall columnist Kurt Schlichter joins the program to discuss his piece about how the actions of Nashville's police force during this week's school shooting shows that bravery and courage is not extinct in America6:20 pm: Chad Saunders, one of the organizers of a referendum against the new Utah State Flag, joins the program to update us on the progress of the referendum6:38 pm: We'll listen back to Rod's conversations this week with Derek Monson, Public Policy Director for the Sutherland Institute, about how to remedy the west's fractured election policies, and (at 6:50 pm) with Christopher Bates, a Legal Fellow with the Orrin Hatch Foundation, about the organization's recent report on a new approach to police reform

donald trump kids school nashville utah protect laws attorney rod deputy director investigations town hall kurt schlichter protect our kids public policy director america first legal john zadrozny sutherland institute knrs rodarquette rodarquetteshow talkradio1059

Political Rewind: Fani Willis considers RICO charges for Trump; YSL trial; GA's Justice System

Political Rewind

Play Episode Listen Later Mar 21, 2023 51:10

Tuesday on Political Rewind: Trump's lawyers filed a motion to dismiss every finding of the Fulton County special grand jury. Meanwhile, a new article suggests the YSL trial in Fulton County is straining resources. Also, a new report from The Urban League highlights inequalities Black Georgians face. The panel: Anthony Michael Kreis, professor of constitutional law, @AnthonyMKreis, Georgia State University Madeline Thigpen, criminal justice reporter, @mthigs, Capital B Tamar Hallerman, senior reporter, @TamarHallerman, The Atlanta Journal-Constitution Tiffany Williams Roberts, Public Policy Director, @twrobertslaw, Southern Center for Human Rights Timestamps: 0:00 - Introduction 4:00 - President Trump filed to stop Fulton County's special grand jury report. 19:00 - The latest on the YSL Fulton County trial and defendant Young Thug. 38:00 - Updates on the Manhattan DA's case against Donald Trump. 41:00 - Senate Bill 44, an anti-gang recruitment bill, passed through the Legislature. 47:00 - Urban League releases state of Black Georgia report. Wednesday on Political Rewind: The AJC's Greg Bluestein joins the panel.

E38 - Nona Jones | Killing Comparison

Moms Unscripted

Play Episode Play 39 sec Highlight Listen Later Jan 31, 2023 37:59

Nona Jones is a rare combination of preacher, business executive, author, and entrepreneur. Her corporate leadership includes serving as the Head of Global Faith Partnerships at Meta, the company formerly known as Facebook, Chief External Affairs Officer for a multi-state school for at-risk girls and Public Policy Director for a multi-service utility company. Our conversation with Nona spans many topics including rejection, comparison, how to be "successful," health and wellness, and more. Listen in! Show NotesFor more information about MOPS International, go to www.mops.org.Find a MOPS group: https://www.mops.org/groupsearch/index.php.Start a MOPS group: https://www.mops.org/start-a-group/.You can connect with Nona through her website at www.nonajones.com and on Instagram, @nonanotnora.Success School --https://www.nonajones.com/schoolKilling Comparison book on Amazon.

AGAINST THE WIND WITH DR. PAUL - EPISODE 079 Featuring: Dr. Paul Thomas, Retired Pediatrician, ATW Host, Author, Kids First 4Ever, and Informed Consent Champion; Bernadette Pajer, Public Policy Director of Informed Choice WA

director amazon mistakes chief progress leveraging boeing tolerance government relations state senate anthony williams cabinet secretary public policy director finer details

Play Episode Listen Later Dec 6, 2022

LISTEN SHOW NOTES: In his From the Heart segment, Dr. Paul shares how grateful he is for all his supporters and the words of encouragement he continues to receive from people. This support has given him the steadfast love, courage and hope he has needed to stay the course in these difficult times. He reassures us that he is never giving up – we are all in this together and are being called to do something magnificent!Next, Dr. Paul addresses the “tripledemic” [...]

11 - Leveraging Tolerance and Understanding to Make Progress| Anthony Williams, Public Policy Director for Amazon

Together at the Top

Play Episode Listen Later Nov 29, 2022 61:23

Anthony Williams comes from humble roots and has earned everything he has achieved. He's worked at the highest levels of just about every pillar of our democratic society, including the judiciary branch for the California Chief Justice, as Chief of Staff to the State Senate, and as Cabinet Secretary to a governor. He's also been managing partner of a successful law firm, Director of Government Relations for Boeing, and now Public Policy Director for Amazon. He's back for a second episode to discuss politics and tolerance in the workplace, how he handles negotiations, and the difference between positive and negative disruption. Anthony opens the show with his thoughts on our current shift into a digital society and economy, particularly on how our sense of connection seems to be eroding while divisions between individuals are growing. This is something he sees a lot of in the workplace, where the differences between the generations are brought into sharp relief. However, he also says he's encouraged by people's increasing willingness to speak up about a lack of tolerance and emphasizes the importance of creating a space where people feel comfortable speaking out. Anthony also speaks about how the power balance between employees and employers is shifting, with remote working becoming normalized and employers finding it more difficult to replace workers, even those with performance issues. Nick then asks some rapid-fire questions of Anthony, including what he looks for in team members and what he avoids, how he handles negotiations, and how young people can catch his attention. And finally, Anthony closes the show by discussing the difference between positive and negative disruptors and why he's in favor of the former. The Finer Details of This Episode: Politics and tolerance in the workplace Location, leverage, and the balance of power What Anthony looks for in team members How Anthony handles negotiations What gets Anthony's attention The role of family Distinguishing between positive and negative disruptors Quotes: “You really have to provide the space for your folks to feel comfortable raising things and speaking up because it improves the overall environment and improves, you know, people are happy at work or are more productive, they're contributing more, they're more bought into the mission. And so you have to create that environment for that to happen.” “Mistakes are not always fatal. We can pretty much always work our way out of a mistake or situation, or some corrective action can be put in place. I'd rather let people feel that they can make mistakes, not because there's some reason to not trust them. Maybe they're taking a risk, right? Maybe, you know, there's a lot that can be happening there. So you don't necessarily lose my trust because you made a mistake.” “I know I hit it right with a person on my team, as an individual and as a member of the team, when they come to me, they say, ‘Here's the situation. I've run into a wall on this, I need your help. Here's how far I've gotten it. Here's what I'm thinking. What do you think? Is that the right way to think about it?' That's one approach. That's the approach I like.” “In any negotiation, you're thinking to yourself, ‘What are they thinking? How are they approaching this?' and it's not easy to do it. But with practice and time and preparation, you can start to chip at it and get some idea of what it is that you're going into and what's happening on the other side of the table. You'll be better prepared, if anything, you'll have some empathy, you'll have some breakthrough on a human level because you understand where they're coming from.” Links: Nick Warner Consulting Together at the Top on YouTube Anthony on Twitter Anthony on LinkedIn

AGAINST THE WIND WITH DR. PAUL - PODCAST 078 Featuring: Ryan Heath, President & CEO of The Gavel Project; and Bernadette Pajer, Public Policy Director of Informed Choice WA

Play Episode Listen Later Nov 28, 2022

LISTEN Show Notes: In his From the Heart segment, Dr. Paul talks about what it means to have consciousness and discernment to perceive truth in fullness. By embracing our struggles with humility and honesty, we gain wisdom and compassion for others. This is how we become a light that overcomes the darkness in the world! Ryan Heath, attorney, civil rights activist, and founder of The Gavel Project, joins the show to discuss his work to protect the freedoms of all Americans, esp [...]

AGAINST THE WIND WITH DR. PAUL - PODCAST EPISODE 074 Featuring: Dr. Denise Sibley, MD, FACP Internal Medicine Physician and Advocate for Medical Freedom; Bernadette Pajer Public Policy Director of Informed Choice WA

Play Episode Listen Later Oct 31, 2022

LISTEN Show Notes: In his From the Heart segment, Dr. Paul discusses the ramifications of the recent vote by the CDC’s Advisory Committee on Immunization Practices (ACIP) to add the Covid shot to the childhood immunization schedule. This is an all risk and zero benefit proposition for kids! Now is the time for parents to draw a line in the sand. We cannot stay silent! Be the truth and be the light. And don't be afraid. Don't be a slave of death. Because that's not [...]

AGAINST THE WIND WITH DR. PAUL - EPISODE 071 FEATURING: Daniel P. Kraft, M.D., M.P.H. Pediatrician and Primary Care Provider; BERNADETTE PAJER PUBLIC POLICY DIRECTOR OF INFORMED CHOICE WA

Play Episode Listen Later Oct 10, 2022

LISTEN Show Notes: In his From the Heart segment, Dr. Paul talks about how to be at peace in the midst of a chaotic world. Having faith over fear and trusting that there is a plan – even when we don’t know what that is in the moment – is the only way to move forward through difficult times. This week Dr. Paul interviews pediatrician and primary care provider, Dr. Dan Kraft. They talk about censorship and negative propaganda in the medical community [...]

AGAINST THE WIND WITH DR. PAUL - EPISODE 070 FEATURING: Dr. Kamli Jura, MD; Pediatrician and Advocate for Informed Consent; Bernadette Pajer Public Policy Director of Informed Choice WA

Play Episode Listen Later Oct 4, 2022

LISTEN Show Notes: In his From the Heart segment, Dr. Paul shares words of wisdom that have helped guide his decision-making lately. First, embrace all things that help us reach our purpose and potential, and reject those things that are hindering progress. Next, he encourages us to ask three questions regarding our thoughts, words, and actions: Is what I’m doing loving and kind? Is it true? Is it helpful? How we answer these questions can help us live by faith and free from fea [...]

AGAINST THE WIND WITH DR. PAUL - EPISODE 068 Featuring: Monique Robles, MD; Pediatric critical care physician and bioethicist, and Bernadette Pajer; Public Policy Director of Informed Choice WA

Play Episode Listen Later Sep 20, 2022

LISTEN Show Notes: In his From the Heart segment, Dr. Paul talks about how we need to surrender to become free and have gratitude to overcome resentment because what we resist persists. He encourages us to break through the world’s endless crazy cycle by choosing to love others, looking for the goodness within them. This week features a dynamite interview with Monique Robles, M.D., a board-certified pediatric critical care physician and bioethicist. She talks [...]

AGAINST THE WIND WITH DR. PAUL - EPISODE 067 FEATURING: Jennifer Margulis, Ph.D. Award-winning science journalist, author, and sought-after speaker; Bernadette Pajer, Public Policy Director of Informed Choice WA

Hillsdale College Podcast Network Superfeed

Play Episode Listen Later Sep 12, 2022

LISTEN Show Notes: In his “From the Heart” segment, Dr. Paul talks about joy and unconditional love. He reminds us that while it is easy to get preoccupied with the demands of life, we have a choice each day to experience the childlike joy of living in the moment. Furthermore, we can choose to love and forgive daily, doing our part to create the kind of world we want to live in. This week, Dr. Paul interviews friend and science journalist, author and speaker, J [...]

Art Laffer on How Incentives Drive the Economy

Play Episode Listen Later Aug 26, 2022 45:05

This week's guests: Art Laffer, Mike Gonzalez, & Gary WolframHost Scot Bertram talks with famed economist Art Laffer about supply-side economics, incentives, and his new online course for Hillsdale College. Mike Gonzalez, senior fellow at the Heritage Foundation, tells us why it's time to stop taxpayer money from flowing to PBS and NPR. And with President Biden's announcement this week on executive action regarding "student loan forgiveness," we listen back to a recent interview on the topic with Gary Wolfram, William Simon Professor of Economics and Public Policy & Director of Economics at Hillsdale.See omnystudio.com/listener for privacy information.

joe biden drive economy economics npr pbs incentives heritage foundation hillsdale college hillsdale mike gonzalez art laffer public policy director gary wolfram

AGAINST THE WIND WITH DR. PAUL - EPISODE 062; Featuring: Dr. Henry Ealy, Founder of, & Executive Community Director for, the Energetic Health Institute; and Bernadette Pajer, Public Policy Director of Informed Choice WA

Play Episode Listen Later Aug 8, 2022

LISTEN In this week’s From the Heart segment, Dr. Paul shares a soul secret that has led him to discover love and spiritual growth while enduring intense hardship. He describes how our pain can lead us to a deeper desire for truth, goodness, and beauty, enabling an experience where our loss can become our gain. Energetic Health Institute executive community director, Dr. Henry Ealy, returns to the show with a Covid special report. We’ll get to the point – the sho [...]

AGAINST THE WIND WITH DR. PAUL - EPISODE 060; FEATURING: Dr. Michelle Perro, MD; Pediatrician, Executive Director GMO Science, and author; Bernadette Pajer, Public Policy Director of Informed Choice WA

Play Episode Listen Later Jul 27, 2022

07272022_show60_podcast.mp3File Size:91802 kbFile Type:mp3Download FileShare with your Friends & FamilyShow Notes:In this week's From the Heart segment, Dr. Paul reveals that he has Covid! Tune in to hear about his experience with symptoms thus far as he is self-isolating in the great outdoors, enjoying some amazing sunshine and fresh air. Dr. Michelle Perro, pediatrician, executive director of GMO Science, and author, joins us to discuss everything Covid-related and how her career [...]

AGAINST THE WIND WITH DR. PAUL-EPISODE 057; FEATURING: Dr. Peter McCullough M.D., M.P.H., Vice Chief of Internal Medicine, Baylor University Medical Center; Bernadette Pajer, Public Policy Director of Informed Choice WA

Play Episode Listen Later Jul 5, 2022

LISTENShare with your Friends & FamilyShow Notes:In his From the Heart segment, Dr. Paul talks about the clash between compassion and judgement as two forces that cannot coexist. We need more compassion combined with courage and honor so that we can speak the truth boldly in a way that brings healing and unity to our broken world! This week Dr. Paul talks everything Covid with Dr. Peter McCullough, M.D., M.P.H., Vice Chief of Internal Medicine, Baylor University Medical Center. They dis [...]

AGAINST THE WIND WITH DR. PAUL-EPISODE 056; Featuring: Megan Redshaw, Children's Health Defense Staff Attorney and Reporter for The Defender; and Bernadette Pajer, Public Policy Director of Informed Choice WA

Play Episode Listen Later Jun 27, 2022

LISTENShare with your Friends & FamilyShow Notes:In this week's From the Heart segment, Dr. Paul highlights the recent CDC campaign promoting “shots for tots” following emergency use authorization of Covid vaccines for infants and toddlers. Now more than ever it is up to us to protect our children! Megan Redshaw, attorney, journalist, and individual rights advocate, sits down with Dr. Paul to run through the recent FDA VRBPAC meetings where decisions were made regarding c [...]

Political Rewind: A reflection on Juneteenth and what the holiday means today

Political Rewind

Play Episode Listen Later Jun 17, 2022 52:37

Friday on Political Rewind: A special Juneteenth episode; our panel examines the history of the holiday and what it means for our democracy. Plus, as legislation restricts how race is taught in schools, what does that mean for future generations? The panel Gavin Godfrey — Editor, Capital B Tiffany Williams Roberts — Public Policy Director, Southern Center for Human Rights Dr. Kurt B. Young — Department Chair, Clark Atlanta University Department of Political Science Jim Galloway — Former political columnist, The Atlanta Journal-Constitution Timestamps :00- Introductions 4:00- Fredrick Douglas comments on freedom on the 4th of July, 1852 10:24- The emancipation frees the slaves, but was it everyone's America? 13:35- During Sherman's march to the see many GA slaves took their own freedom 17:25- The phrase 40 acres and a mule comes from Georgia 26:13- How is reconstruction taught in GA schools? 30:00- Is Juneteenth everyone's holiday to celebrate? 31:20- What does Juneteenth mean to our panelists? 34:29- The wealth gap for Black Americans 39:20- How is the legacy of slavery and racism taught in GA schools? 44:00- How can we fulfill the promise of Juneteenth? Please be sure to download our newsletter: www.gpb.org/newsletters. And subscribe, follow and rate this show wherever podcasts are found.

america holiday political reflection ga human rights juneteenth political science black americans frederick douglass department chair public policy director southern center jim galloway

AGAINST THE WIND WITH DR. PAUL - EPISODE 052: FEATURED GUESTS: Dr. Joel Wallskog Orthopedic Surgeon, Cvd Jab Injured and Co-Chair React19; Beatrice BirchInner, Fire Founder; BERNADETTE PAJER, PUBLIC POLICY DIRECTOR OF INFORMED CHOICE WA